Loading stock data…
$2.05+0.01 (+0.64%)
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States.
Sera Prognostics, Inc. in the Healthcare sector is trading at $2.05 with a market capitalization of $79M. Wall Street consensus targets $5.50 (2 analysts), implying a +167.9% move over the next 12 months. The stock is currently 48% below its 52-week high of $3.95, remaining 7.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $30,000↑ | $14,000↑ | $10,000↓ | $16,000↓ | $17,000 |
| Gross Profit | -$20,000↑ | -$28,000↑ | -$32,000↓ | -$25,000↓ | -$24,000 |
| Operating Income | -$10.00M↓ | -$9.36M↓ | -$8.95M↑ | -$8.98M↑ | -$9.32M |
| Net Income | -$9.14M↓ | -$8.40M↓ | -$7.88M↓ | -$7.81M↑ | -$8.05M |
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test...